Skip to search formSkip to main contentSkip to account menu

AZD0865

National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

ImidazolesPyridines
linaprazan

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Predictors of either rapid healing or refractory reflux oesophagitis during treatment with potent acid suppression
Little is known regarding patient characteristics that influence the speed of reflux oesophagitis (RO) healing. 
2012
2012
An In Vitro Methodology for Forecasting Luminal Concentrations and Precipitation of Highly Permeable Lipophilic Weak Bases in the Fasted Upper Small Intestine
To develop an in vitro methodology for prediction of concentrations and potential precipitation of highly permeable, lipophilic… 
2011
2011
Co-administration of a nanosuspension of a poorly soluble basic compound and a solution of a proton pump inhibitor—the importance of gastrointestinal pH and solubility for the in vivo exposure
In Sigfridsson et al. (2011, Drug Dev Ind Pharm, 37:243–251), there was no difference in plasma concentration of BA99 when… 
Review
2011
Review
2011
A Phase II, Randomized, Double-Blind, Placebo Controlled, Three Period, Crossover, Single Center Study to Evaluate the Effects of Naronapride on Esophageal and Gastric pH and Reflux Events in…
2005
2005
Consistent inhibition of acid output with repeated dosing of AZD0865 in rats
2004
2004
AZD0865, A POTASSIUM-COMPETITIVE ACID BLOCKER (P-CAB), HAS A LONG DURATION OF EFFECT IN THE RAT: 22
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)